総合安全衛生管理機構

研究分野

ライフサイエンス / 衛生学、公衆衛生学分野：実験系を含まない /
ライフサイエンス / 消化器内科学 /

論文

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.

Keita Ogawa Hiroaki Kanzaki Tetsuhiro Chiba Junjie Ao Na Qiang Yaojia Ma Jiaqi Zhang Sae Yumita Takamasa Ishino Hidemi Unozawa Motoyasu Kan Terunao Iwanaga Miyuki Nakagawa Kisako Fujiwara Naoto Fujita Takafumi Sakuma Keisuke Koroki Yuko Kusakabe Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Ryo Nakagawa Sadahisa Ogasawara Eiichiro Suzuki Shingo Nakamoto Ryosuke Muroyama Tatsuo Kanda Hitoshi Maruyama Naoya Mimura Jun Kato Shinichiro Motohashi Naoya Kato

Journal of Cancer 13(8) 2656-2661 2022年

Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought a major paradigm shift in the treatment...

Changes in therapeutic options for hepatocellular carcinoma in Asia.

Sadahisa Ogasawara Keisuke Koroki Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Naoya Kato

Liver international : official journal of the International Association for the Study of the Liver 42(9) 2055-2066 2021年11月

The incidence rate of hepatocellular carcinoma (HCC) is expected to increase, with most cases occurring in Asia. In some parts of Asia, the occurrence of HCC developing from metabolic-related liver disease has markedly increased in recent years, w...

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.

Yuko Kusakabe Tetsuhiro Chiba Motohiko Oshima Shuhei Koide Ola Rizq Kazumasa Aoyama Junjie Ao Tatsuya Kaneko Hiroaki Kanzaki Kengo Kanayama Takahiro Maeda Tomoko Saito Ryo Nakagawa Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Sadahisa Ogasawara Eiichiro Suzuki Shingo Nakamoto Shin Yasui Rintaro Mikata Ryosuke Muroyama Tatsuo Kanda Hitoshi Maruyama Jun Kato Naoya Mimura Anqi Ma Jian Jin Yoh Zen Masayuki Otsuka Atsushi Kaneda Atsushi Iwama Naoya Kato

Scientific reports 11(1) 21396-21396 2021年11月

Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression o...

Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment.

Shohei Mukai Hiroaki Kanzaki Sadahisa Ogasawara Takamasa Ishino Keita Ogawa Miyuki Nakagawa Kisako Fujiwara Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Keisuke Koroki Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Ryosuke Muroyama Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Jun Kato Manayu Shiina Masayuki Ota Jun-Ichiro Ikeda Yuichi Takiguchi Masayuki Ohtsuka Naoya Kato

JGH open : an open access journal of gastroenterology and hepatology 5(11) 1266-1274 2021年11月

BACKGROUND AND AIM: Immune checkpoint inhibitors and their combination with other agents have recently been available in advanced hepatocellular carcinoma (HCC). Hence, a thorough understanding of the tumor microenvironment based on tumor samples ...

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Keisuke Koroki Naoya Kanogawa Susumu Maruta Sadahisa Ogasawara Yotaro Iino Masamichi Obu Tomomi Okubo Norio Itokawa Takahiro Maeda Masanori Inoue Yuki Haga Atsuyoshi Seki Shinichiro Okabe Yoshihiro Koma Ryosaku Azemoto Masanori Atsukawa Ei Itobayashi Kenji Ito Nobuyuki Sugiura Hideaki Mizumoto Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Tomoko Saito Takayuki Kondo Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Naoya Kato

Liver cancer 10(5) 473-484 2021年9月

BACKGROUND: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore can...

MISC

12 3 4 5 >

新規食餌誘導性非アルコール性脂肪性肝疾患モデルマウスの構築と経口血糖降下薬による治療効果の検証

佐久間崇文中村昌人千葉哲博敖俊傑強娜小川慶太岩永光巨菅元泰藤田尚人神崎洋彰興梠慧輔小林和史清野宗一郎叶川直哉齊藤朋子中川良近藤孝行小笠原定久中本晋吾室山良介加藤直也

肝臓 63(Suppl.1) A310-A310 2022年4月

進行肝細胞癌におけるGd-EOB-DTPA-enhanced MRI肝細胞相・高信号結節のアテゾリズマブ・ベバシズマブ併用療法の有効性の検証

弓田冴小笠原定久叶川直哉岩永光巨宇野澤秀美藤原希彩子中川美由貴佐久間崇文藤田尚人神崎洋彰興梠慧輔小林和史中村昌人清野宗一郎近藤孝行齊藤朋子中川良中本晋吾室山良介千葉哲博加藤直也

肝臓 63(Suppl.1) A327-A327 2022年4月

RNA結合蛋白ELAVL1のB型肝炎ウイルス複製と肝細胞癌増殖への関わり

神崎洋彰千葉哲博興梠慧輔日下部裕子小林和史叶川直哉清野宗一郎中村昌人近藤孝行齊藤朋子中川良小笠原定久室山良介中本晋吾神田達郎丸山紀史加藤順關場一磨大塚基之大塚将之加藤直也

肝臓 63(Suppl.1) A335-A335 2022年4月

肝細胞癌におけるCTNNB1遺伝子変異とアテゾリズマブ/ベバシズマブ併用療法の初期治療効果の関連性の検討

小川慶太千葉哲博岩永光巨菅元泰強娜敖俊傑佐久間崇文藤田尚人神崎洋彰興梠慧輔小林和史清野宗一郎中村昌人叶川直哉齊藤朋子近藤孝行中川良小笠原定久中本晋吾室山良介加藤直也

肝臓 63(Suppl.1) A336-A336 2022年4月

今後のトレンドを加味した肝細胞癌治療後のフォローアップ間隔の緩和の可能性の検討

叶川直哉小笠原定久岩永光巨宇野澤秀美中川美由貴藤原希彩子佐久間崇文藤田尚人神崎洋彰興梠慧輔小林和史清野宗一郎中村昌人齊藤朋子近藤孝行中川良中本晋吾室山良介千葉哲博加藤直也

肝臓 63(Suppl.1) A422-A422 2022年4月

共同研究・競争的資金等の研究課題

大学における高度肥満学生の非アルコール性脂肪性肝疾患(NAFLD)についての検討
日本学術振興会: 科学研究費助成事業
齊藤朋子

研究期間: 2020年4月 - 2023年3月

メニュー/MENU

齊藤 朋子

研究分野

論文

MISC

共同研究・競争的資金等の研究課題

齊藤朋子